Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05592912
Other study ID # HL-001
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date January 1, 2024
Est. completion date January 1, 2025

Study information

Verified date May 2023
Source PromiSight, LLC
Contact Jodi S Pitcher
Phone 513-961-8200
Email jlpitcher@crc-regulatory.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to provide safety data for two different dosages of HydroLenz. Secondary objectives are to provide preliminary data to determine whether HydroLenz has the same effect in humans as it does in the porcine model; to confirm the reliability of methods for evaluating lens opacity; and, to acquire information that can be used to design the pivotal study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 36
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Male or female of any race. 2. 65 years of age or older. 3. Study eye is phakic and scheduled for pars plana vitrectomy (23, 25, or 27 gauge) for epiretinal membrane or vitreomacular traction surgery. 4. Willingness and ability to comply with schedule for follow-up visits. 5. Subject understands the study requirements and the treatment procedures and provides signed, written informed consent obtained in accordance with the institutional review board (or ethics committee) requirements for this first-in-man early feasibility study. Exclusion Criteria: 1. Aphakic or pseudophakic lens status in either or both eyes. 2. History of previous cataract surgery in either eye. 3. Evidence of congenital cataract. 4. Study eye with corneal opacity of one of the following LOCS III grades or condition that would confound the LOCS III grading results: 1. Inability to grade opacities in the study eye with LOCS III at the baseline exam; 2. Inability to dilate pupil to at least 6.0 mm; 3. LOCS III grade = 2 for nuclear opalescence, cortical lens opacities, or posterior subcapsular lens opacities in the study eye at baseline. 5. Diabetic retinopathy or macular edema in the study eye. 6. Retinal vascular disease or retinopathy in the study eye. 7. History of previous intravitreal injections in the study eye. 8. History of previous subconjunctival injections in the study eye. 9. History of previous radiation in the study eye. 10. History of systemic, periocular, inhaled, or chronic topical corticosteroids. 11. Previous laser prophylaxis for retinal tear/hole/lattice degeneration in the study eye. 12. Previous pneumatic retinopexy or retinal detachment repair in the study eye. 13. Previous vitrectomy in the study eye. 14. Previous laser treatment anywhere in the study eye (trabecular meshwork, iris, retina, macula). 15. Use of silicone oil, air or gas tamponade during the vitrectomy in the study eye prior to injection of the HydroLenz. 16. Use of binocular indirect ophthalmoscopy laser during the procedure (endolaser is permitted). 17. History of any previous ocular surgery in the study eye. 18. Any ocular trauma resulting in lens opacity or subluxation of the lens in the study eye. 19. Iatrogenic lens trauma during surgery prior to injection of the HydroLenz. 20. Surgical plan for the vitrectomy includes planned glaucoma filtering or tube-shunt procedure or any procedure affecting the lens. 21. Female patients who are pregnant or lactating or plan to become pregnant during the course of the study. 22. A known sensitivity to study medications for which no alternative medication can be - prescribed. 23. Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the HydroLenz treatment or study participation or may confound the outcome of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HydroLenz Injection
The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
Other:
No HydroLenz Injection
No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
PromiSight, LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Changes in Lens Opacities The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities. Baseline and 6 Months
Primary Evaluation of Changes in Lens Opacities The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities. Baseline and 12 Months
Primary Changes in BSCVA Number of eyes losing more than 2 lines of BSCVA Baseline and 6 Months
Primary Changes in BSCVA Number of eyes losing more than 2 lines of BSCVA Baseline and 12 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05990829 - Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial Phase 4
Recruiting NCT05631054 - Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
Recruiting NCT05728476 - Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema N/A
Recruiting NCT04774146 - Quantification of Silicone Oil Emulsification After Pars Plana Vitrectomy
Completed NCT04278079 - Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy N/A
Completed NCT05013281 - Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
Completed NCT00548197 - Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Phase 1
Terminated NCT00936520 - SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy Phase 1
Recruiting NCT05248334 - A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy Phase 1